Pyrazole has the molecular formula C3H4N2 and CAS registry number 288-13-1. It is a five-membered aromatic nitrogen heterocycle containing two adjacent nitrogen atoms (1,2-diazole) and conforms to Hückel's 6π-electron aromatic system. At ambient temperature, it appears as white needle-shaped crystals with a pyridine-like odor. Its melting point is 66–70 °C and boiling point approximately 187 °C. It is soluble in water, alcohols, ethers and other solvents and exhibits weak basicity.Representative pharmaceutical examples include celecoxib, a COX-2 anti-inflammatory inhibitor. In agrochemicals, it structures are widely deployed in insecticides, fungicides and herbicides (such as fipronil-type products).
|
|
|
| Chemical Formula | C3H4N2 |
| Exact Mass | 68.04 |
| Molecular Weight | 68.08 |
| m/z | 68.04 (100.0%), 69.04 (3.2%) |
| Elemental Analysis | C, 52.93; H, 5.92; N, 41.15 |
Pyrazole (α-yrromonazole) derivatives have garnered significant attention in scientific research due to their potential as inhibitors of cyclooxygenase-2 (COX-2). COX-2 is a key enzyme involved in the inflammatory response and the production of prostaglandins, which mediate pain, fever, and inflammation. By inhibiting COX-2, α-yrromonazole-based compounds can effectively reduce inflammation and pain, offering a therapeutic benefit in the treatment of various inflammatory conditions and pain syndromes.
One of the notable advantages of α-yrromonazole-based COX-2 inhibitors is their ability to provide relief from inflammation and pain without causing significant gastrointestinal side effects, which are common with non-selective COX inhibitors that also inhibit COX-1, the constitutive form of the enzyme expressed in most tissues.
The selective inhibition of COX-2 allows for a more targeted therapeutic approach, minimizing adverse effects on other physiological processes.
Research on the derivatives as COX-2 inhibitors has led to the development of several clinically important drugs, such as celecoxib and etoricoxib. These drugs are widely used in the management of conditions such as osteoarthritis, rheumatoid arthritis, and acute pain, demonstrating the significant impact of α-yrromonazole-based inhibitors on patient care.
The versatility chemistry also allows for the synthesis of a wide range of derivatives with different pharmacological profiles, providing opportunities for the development of new and improved COX-2 inhibitors with enhanced efficacy, safety, and patient compliance.
In conclusion, the derivatives have emerged as crucial inhibitors of COX-2, playing a vital role in the development of anti-inflammatory and analgesic drugs. Their ability to selectively inhibit COX-2 while minimizing gastrointestinal side effects has made them a valuable addition to the therapeutic arsenal for the management of inflammatory conditions and pain.
Antimicrobial Agents
Studies have shown that by joining together the ring and the rhodanine structure with antibacterial activity, new compounds with significant antibacterial activity can be designed. These compounds showed significant inhibitory effects on drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus in in vitro experiments, demonstrating their potential in the development of new antibiotics.
1. Antibacterial activity
Certain compounds among the derivatives have been shown to have significant antibacterial activity against a variety of bacteria, including Gram-positive and Gram-negative bacteria. This provides a theoretical basis for the development of new antibiotics.
Low toxicity
Compared with some traditional antibiotics, the derivatives generally have lower toxicity, which means they may cause less burden on the patient's body during treatment.
Prospects for drug development
Due to the multi-directional nature of the substituents on the ring, chemists can modify the compounds through different modifying groups in order to screen for compounds with better antibacterial activity. This provides rich possibilities for the development of new antibiotics.
Although not all PPIs contain pyrazole, some structures similar to it are present in PPIs like pantoprazole and rabeprazole, which are used to treat gastrointestinal diseases such as peptic ulcers and reflux esophagitis by inhibiting gastric acid secretion.
Sensors
α-yrromonazole-based sensors have been developed for detecting various analytes, including gases and biological molecules, due to their sensitivity and selectivity.
The working principle of α-yrromonazole-based sensors usually involves the synergistic effect of molecular recognition elements and transducers.
The molecular recognition element can specifically recognize the target analyte and convert it into a measurable signal through chemical or physical action. The transducer is responsible for converting this signal into an electrical signal or other readable signal form, thereby achieving quantitative detection of the analyte.
High Sensitivity
Pyrazol-based sensors can detect extremely low concentrations of analytes, which is crucial for early warning and accurate measurement.
High Selectivity
By designing specific molecular recognition elements, pyrazol-based sensors can achieve selective detection of target analytes and avoid interference.
Fast Response Speed
Pyrazol-based sensors generally have a fast response time and can provide accurate detection results in a short time.
Pyrazole, a heterocyclic compound containing nitrogen, has shown immense potential and versatility across various fields, particularly in pharmaceuticals, pesticides, and other chemicals. Looking ahead, the research trends exhibit a promising landscape, driven by its unique properties and growing applications.
In the pharmaceutical industry, α-yrromonazole-based drugs have gained significant attention due to their therapeutic efficacy. The approval of pirtobrutinib by the FDA for treating relapsed or refractory mantle cell lymphoma (MCL) in 2023 exemplifies this trend. The presence of the 1H-α-yrromonazole moiety in pirtobrutinib underscores its importance in drug discovery. Future research is likely to focus on synthesizing novel derivatives with enhanced bioactivity and selectivity, targeting various diseases.
Moreover, the pesticides have demonstrated remarkable effectiveness in controlling pests, making them a key area of focus for agricultural research. With the increasing demand for sustainable and eco-friendly pesticides, researchers are exploring α-yrromonazole-based compounds that are less harmful to the environment while maintaining high efficacy.
Beyond pharmaceuticals and pesticides, its applications in dyes, coatings, pigments, fragrances, food colorants, photographic chemicals, and other functional materials are also expanding. Researchers are continuously innovating to develop new α-yrromonazole-based materials with improved properties and broader applications.In conclusion, the future research trends are poised for significant growth, driven by its diverse applications and the ongoing need for innovative solutions. With advancements in synthetic methodologies and increasing understanding of biological activities, the horizon for α-yrromonazole-based research appears boundless.
The Development History and Key Years
As a five membered heterocyclic compound containing two adjacent nitrogen atoms, its development has spanned three major stages: chemical structure exploration, agricultural revolution, and pharmaceutical innovation. Multiple key years have marked technological breakthroughs and industrial transformation.
German chemist Ludwig Knorr synthesized 1-phenyl-3-methylpyrazolone for the first time through the cyclization reaction of ethyl acetoacetate and phenylhydrazine while studying quinine analogues, and named the five membered heterocyclic structure "α-yrromonazole" for the first time. This naming laid the foundation for α-yrromonazole compounds.
Buchner independently prepared pure α-yrromonazole through other methods and confirmed its structure. At the same time, he discovered α-yrromonazole alanine, which only exists in pumpkin seeds and watermelon seeds in nature, further stimulating the research interest of the chemical community in α-yrromonazole.
American scientist Thampson first reported the activity of 2-α-yrromonazole-5-one and 3-α-yrromonazole-5-one in inhibiting plant growth, marking the beginning of research on α-yrromonazole as pesticides.
The Swiss company Geigy (now the predecessor of Syngenta) introduced the product rings into organophosphate and carbamate pesticides, developing insecticides such as imidacloprid, esomeprazole, and α-yrromonazole, as well as new varieties such as α-yrromonazole oxyphosphate and α-yrromonazole thion. These compounds, with their high efficiency and low toxicity, quickly became the mainstay of agricultural pest control, marking the transition of α-yrromonazole from laboratory to industrial applications.
Scientists developed methoxy acrylate fungicides through structural modification based on the unique mechanism of action of natural β - acrylate derivatives, such as Oudemansin A discovered in 1969 and Strobilurin A isolated in 1977.
BASF launched the world's first commercially available product, ether fungicide (Cuibei).
imus explicabo ipsam doloribus expedita, nulla laudantium odit tempora dolor ratione voluptatum, rerum impedit eius culpa? Iste?.
Syngenta launched azoxystrobin (amisida).
BASF further launched pyraclostrobin (Kerun), which had the highest activity and became the first registered fungicide for crop health, pioneering the concept of "preventive protection". During this period, pyraclostrobin, with its broad-spectrum, high efficiency, and low toxicity, has long dominated the global fungicide market.
The patent for α-yrromonazole ether fungicide expired in China, triggering a wave of domestic enterprise registration.
According to statistics, there are over 108 registration certificates for α-yrromonazole fungicides in China, involving more than 50 enterprises, and the market benefits continue to expand. At the same time, breakthroughs have been made in the research of α-yrromonazole compounds in the pharmaceutical field, and their derivatives have been proven to have various pharmacological activities such as antibacterial, anti-tumor, and anti-inflammatory, becoming a hot topic in new drug development. For example, the demand for 1,4-dimethylpyrazole in the pharmaceutical industry accounts for as much as 60%, and it is expected that the market size will exceed 5 billion yuan by 2030.
The Knorr method is the core route for pyrazole synthesis, using 1,3‑dicarbonyl compounds (e.g., acetylacetone, β‑keto esters) and hydrazine as starting materials, with cyclocondensation under acid catalysis. Taking acetylacetone and hydrazine hydrate as an example, refluxing in ethanol affords 3,5‑dimethylpyrazole in one step via nucleophilic addition, dehydration, and cyclization, with a yield of over 85%. Featuring readily available starting materials, mild conditions (0–100 °C), and simple operation, this method gives a single product from symmetric substrates and is the first choice for laboratory and industrial preparation of α-yrromonazole.
α,β‑Unsaturated aldehydes or ketones first undergo Michael addition with hydrazine to form pyrazoline intermediates, which are then converted to α-yrromonazole via oxidative dehydrogenation. For instance, cinnamaldehyde reacts with hydrazine in ethanol to yield 4,5‑dihydropyrazole, which can be oxidized to the target product using manganese dioxide or air. This method is suitable for constructing 4‑aryl‑substituted α-yrromonazole and allows flexible modification of substituents, complementing the limitations of the Knorr method in asymmetric substitution.
Diazo compounds undergo [3+2] cycloaddition with alkynes under copper or palladium catalysis to directly construct the α-yrromonazole ring. Using diazomethane and acetylene as an example, the reaction proceeds at room temperature under CuI catalysis to form α-yrromonazole with high selectivity, achieving 100% atom economy. This method exhibits excellent regioselectivity and is suitable for the synthesis of polysubstituted α-yrromonazole, especially for the precise preparation of pharmaceutical and functional molecules.
In recent years, multicomponent one‑pot reactions and direct C‑H functionalization strategies have been developed. For example, α-yrromonazole can be synthesized in one pot from aldehydes, alkynes, and hydrazines under acid catalysis, greatly simplifying procedures. Transition‑metal‑catalyzed (Pd, Rh) or photocatalytic C‑H activation enables direct introduction of substituents onto the α-yrromonazole ring without pre‑functionalization, meeting green chemistry requirements and emerging as a new direction for industrialization.
Tautomerism and Acid–Base Properties
α-yrromonazole exhibits tautomerism between 1H-pyrazole and 2H-pyrazole; the dominant form in solution at ambient temperature and in the solid state is 1H-pyrazole. The two ring nitrogen atoms display markedly different chemical behavior: the pyrrole-type N–H is weakly acidic, while the pyridine-type nitrogen bears a lone electron pair and shows weak basicity, with a conjugate-acid pKa of approximately 2.5, making it substantially less basic than imidazole. Strong intermolecular hydrogen bonding leads to higher melting and boiling points than structurally related five-membered nitrogen heterocycles.
Reactivity and Coordination Behavior
As an aromatic heterocycle, α-yrromonazole undergoes electrophilic substitution preferentially at the C4 position. Deprotonation by strong base yields the pyrazolate anion, which readily undergoes derivatization such as N-alkylation and N-acylation. The pyridine-type nitrogen acts as a coordination site and can bind a variety of transition-metal ions either as a monodentate ligand or a bridging ligand, finding broad use in coordination chemistry and the synthesis of functional coordination complexes.
Stability, Spectroscopy and Safety Profile
α-yrromonazole possesses good thermal stability and resists decomposition under atmospheric-pressure distillation; however, its aromatic ring is susceptible to ring-opening degradation under strongly oxidizing or strongly acidic harsh conditions. The compound shows characteristic absorption in the near-ultraviolet region, enabling UV detection in liquid chromatography. α-yrromonazole irritates mucous membranes and skin; direct contact may cause erythema and discomfort. Storage should exclude strong oxidants and strong acids. Keep the material sealed in a cool, well-ventilated area and avoid co-storage with reactive reagents.
FAQ
What is pyrazole used for?
+
-
Pyrazole derivatives have a wide range of uses, most notably in medicine as anti-inflammatory drugs (like celecoxib), anticancer agents, and treatments for bacterial infections, HIV, and glaucoma. They are also used in agriculture as pesticides, such as fungicides and insecticides, and in research for their role as enzyme inhibitors and ligands.
Medical
Is pyrazole toxic?
+
-
Pyrazole contamination in water can have both short and long-term adverse effects. Studies have shown that pyrazole and its derivatives are toxic to aquatic organisms, including fish and other aquatic species.
What is pyrazole also known as?
+
-
In 1883 Ludwig Knorr was first to abbreviate the term of pyrazole. The first natural pyrazole is 1-pyrazole-alanine which was isolated in 1959 from watermelon seeds1,2. Pyrazoles are also known as azoles3 and pyrazoles act as ligands for different Lewis acids3.
Which of the following drugs has pyrazole?
+
-
Pyrazole derivatives have exhibited a broad spectrum of biological activities, and approved pyrazole-containing drugs include celecoxib, antipyrine, phenylbutazone, rimonabant, and dipyrone.
What is a substituted pyrazole?
+
-
Synthesis of pyrazoles substituted by thiophene moiety 29 could be carried during the reaction of chalcone-type compound 28 with phenyl hydrazine hydrochloride 4-HCl via 3 + 2 annulations (Scheme 13). The obtained thiophene-pyrazole hybrids 29 were screened as antimicrobial and antioxidant agents (Scheme 13).
Hot Tags: pyrazole cas 288-13-1, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, L Sulforaphane CAS 142825 10 3, Primidone powder, Chlorpropham CAS 101 21 3, Chenodeoxycholic Acid CDCA CAS 474 25 9, Chrysophanic Acid CAS 481 74 3, 3-Hydroxytyramine